October 10, 2011
Takeda Pharmaceutical announced on September 26 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Edarbi (azilsartan medoxomil), a new angiotensin II receptor blocker (ARB) for the...read more